CancerIQ is an early cancer detection and prevention diagnostic tool that offers a risk assessment solution to help clinicians calculate an individual’s risk of developing cancer. The calculation is based on an individual’s family history, genetics, and lifestyle among other factors. The platform then directs patients to appropriate care pathways for prevention and care, which could include MRIs, multi-cancer early detection tests, and lifestyle interventions. The platform also provides information on available clinical trials, as well as educational and social resources. As of March 2022, it was used by healthcare providers in 180 locations across the US.
The company says it is the first and only precision cancer prevention solution that can be used by primary and preventive care providers in addition to cancer specialists. The platform integrates directly into real-time EHR workflows such as Cerner and Epic, allowing it to gather patient data and offer personalized recommendations. This integration allows providers in any care setting to have access to the latest genomic research, clinical guidelines, and life science innovations. The company has partnered with and received funding from OSF HealthCare, the first hospital system to adopt CancerIQ. CancerIQ plans to expand its usage throughout OSF hospitals and clinics.
Its latest funding round took place in March 2022, where it raised USD 14 million in a Series B financing round co-led by Merck Global Health Innovation Fund and Amgen Ventures. The funds have been earmarked for expanding patient access as well as enhancing its platform and increasing partnerships with hospital systems.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.